DK4349406T3 - Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel - Google Patents

Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel

Info

Publication number
DK4349406T3
DK4349406T3 DK24152053.5T DK24152053T DK4349406T3 DK 4349406 T3 DK4349406 T3 DK 4349406T3 DK 24152053 T DK24152053 T DK 24152053T DK 4349406 T3 DK4349406 T3 DK 4349406T3
Authority
DK
Denmark
Prior art keywords
benzoxazole
dichlorophenyl
carboxy
crystalline solid
solid forms
Prior art date
Application number
DK24152053.5T
Other languages
Danish (da)
English (en)
Inventor
Kevin Paul Girard
Andrew J Jensen
Kris Nicole Jones
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54199901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4349406(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK4349406T3 publication Critical patent/DK4349406T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
DK24152053.5T 2014-09-08 2015-08-31 Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel DK4349406T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462047614P 2014-09-08 2014-09-08
US201562203953P 2015-08-12 2015-08-12
EP21203965.5A EP3977993B1 (en) 2014-09-08 2015-08-31 Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament

Publications (1)

Publication Number Publication Date
DK4349406T3 true DK4349406T3 (da) 2026-02-02

Family

ID=54199901

Family Applications (2)

Application Number Title Priority Date Filing Date
DK24152053.5T DK4349406T3 (da) 2014-09-08 2015-08-31 Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel
DK21203965.5T DK3977993T3 (da) 2014-09-08 2015-08-31 Krystallinske faste former af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til anvendelse som et medikament

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21203965.5T DK3977993T3 (da) 2014-09-08 2015-08-31 Krystallinske faste former af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til anvendelse som et medikament

Country Status (24)

Country Link
US (1) US9770441B1 (https=)
EP (3) EP3977993B1 (https=)
JP (5) JP2016065042A (https=)
KR (1) KR102004059B1 (https=)
CN (2) CN115368313A (https=)
AU (1) AU2015313875B2 (https=)
BR (1) BR112017003421B1 (https=)
CA (1) CA2903194A1 (https=)
CY (1) CY1124843T1 (https=)
DK (2) DK4349406T3 (https=)
ES (3) ES2901785T3 (https=)
FI (2) FI4349406T3 (https=)
HR (1) HRP20211834T1 (https=)
HU (2) HUE065233T2 (https=)
IL (1) IL251037B1 (https=)
LT (1) LT3191461T (https=)
MX (1) MX374012B (https=)
PL (3) PL3191461T3 (https=)
PT (3) PT4349406T (https=)
RS (1) RS62634B1 (https=)
SG (1) SG11201700958YA (https=)
SI (3) SI4349406T1 (https=)
TW (1) TWI644902B (https=)
WO (1) WO2016038500A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
US12116352B2 (en) 2019-04-11 2024-10-15 Inke, S.A. Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
EP3969443B1 (en) * 2019-05-16 2024-11-20 Teva Pharmaceuticals International GmbH Solid state forms of tafamidis and salts thereof
US20220251052A1 (en) * 2019-07-04 2022-08-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021093809A1 (zh) 2019-11-15 2021-05-20 苏州科睿思制药有限公司 他发米帝司的晶型及其制备方法和用途
EP4077287B1 (en) * 2019-12-20 2025-11-19 Pfizer Ireland Pharmaceuticals Unlimited Company Efficient process for making 6-carboxy benzoxazole derivatives
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2021232619A1 (zh) * 2020-05-19 2021-11-25 苏州科睿思制药有限公司 一种他发米帝司游离酸的晶型及其制备方法和用途
US20230265059A1 (en) * 2020-07-04 2023-08-24 Nuray Chemicals Private Limited Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof
US12522573B2 (en) * 2020-10-19 2026-01-13 Alivus Life Sciences Limited Process for preparation of tafamidis and salts thereof
WO2022107166A1 (en) * 2020-11-20 2022-05-27 Natco Pharma Limited Novel crystalline form of tafamidis and its process thereof
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN114907283B (zh) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
CN114989106A (zh) * 2021-02-09 2022-09-02 齐鲁制药有限公司 氯苯唑酸的新晶型及其制备方法
EP4083027A1 (en) * 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
US20250042864A1 (en) 2021-11-17 2025-02-06 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
CN119604278A (zh) 2022-07-28 2025-03-11 辉瑞大药厂 氯苯唑酸药物组合物
WO2024084362A1 (en) * 2022-10-17 2024-04-25 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of crystalline form of tafamidis
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
WO2026050334A1 (en) 2024-08-29 2026-03-05 Alexion Pharmaceuticals, Inc. Transthyretin stabilizers and methods of use thereof
EP4717262A1 (en) 2024-09-26 2026-04-01 Galenicum Health S.L.U. Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
EP4717261A1 (en) 2024-09-26 2026-04-01 Galenicum Health S.L.U. Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2800237C (en) 2002-12-19 2016-05-17 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
CN103951583B (zh) * 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
RU2586330C2 (ru) * 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
EP3969443B1 (en) 2019-05-16 2024-11-20 Teva Pharmaceuticals International GmbH Solid state forms of tafamidis and salts thereof
US20220251052A1 (en) 2019-07-04 2022-08-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021152623A1 (en) 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt

Also Published As

Publication number Publication date
FI4349406T3 (fi) 2026-02-04
SI4349406T1 (sl) 2026-02-27
WO2016038500A1 (en) 2016-03-17
TWI644902B (zh) 2018-12-21
EP4349406A3 (en) 2024-05-22
FI3977993T3 (fi) 2024-03-25
JP2016065042A (ja) 2016-04-28
IL251037B1 (en) 2024-10-01
CN115368313A (zh) 2022-11-22
SI3191461T1 (sl) 2022-01-31
JP7357525B2 (ja) 2023-10-06
KR20170040314A (ko) 2017-04-12
HUE056583T2 (hu) 2022-02-28
MX374012B (es) 2020-07-22
PT3191461T (pt) 2021-12-27
PT3977993T (pt) 2024-04-01
EP3977993A1 (en) 2022-04-06
RS62634B1 (sr) 2021-12-31
PL3191461T3 (pl) 2022-02-07
ES2975633T3 (es) 2024-07-10
PL4349406T3 (pl) 2026-03-23
ES2901785T3 (es) 2022-03-23
JP2022024014A (ja) 2022-02-08
ES3061774T3 (en) 2026-04-07
CY1124843T1 (el) 2022-11-25
EP4349406A2 (en) 2024-04-10
BR112017003421A2 (pt) 2017-11-28
BR112017003421B1 (pt) 2023-10-10
EP3191461A1 (en) 2017-07-19
US9770441B1 (en) 2017-09-26
KR102004059B1 (ko) 2019-07-25
AU2015313875B2 (en) 2018-03-15
SG11201700958YA (en) 2017-03-30
CN106715405A (zh) 2017-05-24
AU2015313875A1 (en) 2017-03-02
TW201613880A (en) 2016-04-16
HRP20211834T1 (hr) 2022-03-04
RU2017107235A (ru) 2018-10-11
IL251037A0 (en) 2017-04-30
PL3977993T3 (pl) 2024-05-06
DK3977993T3 (da) 2024-02-19
HUE065233T2 (hu) 2024-05-28
JP2020055832A (ja) 2020-04-09
EP3191461B1 (en) 2021-11-03
EP4349406B1 (en) 2025-12-03
SI3977993T1 (sl) 2024-05-31
US20170273953A1 (en) 2017-09-28
JP2025108584A (ja) 2025-07-23
NZ766084A (en) 2023-12-22
CA2903194A1 (en) 2016-03-08
RU2017107235A3 (https=) 2018-10-11
JP2023134645A (ja) 2023-09-27
MX2017002954A (es) 2017-06-15
NZ729011A (en) 2023-10-27
PT4349406T (pt) 2026-02-04
LT3191461T (lt) 2021-12-10
RU2692252C2 (ru) 2019-06-24
EP3977993B1 (en) 2024-01-31

Similar Documents

Publication Publication Date Title
DK4349406T3 (da) Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel
IL283258A (en) Treatment of hypoparathyroidism
IL250239A0 (en) Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
DK3094631T4 (da) Pyrimidinyloxybenzenderivater som herbicider
HUE042409T2 (hu) Eljárás diaril-tiohidantoin vegyület elõállítására
DK3130592T3 (da) ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
DK3099333T3 (da) Bag3 som mål for behandling af hjertesvigt
EP3143060B8 (en) Catalysts for the synthesis of oxazolidinone compounds
DK3189043T3 (da) Terapeutiske forbindelser som hæmmere af orexin-1-receptoren
ZA201700022B (en) A novel formulation of meloxicam
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
HUE042349T2 (hu) Eljárás diariltiohidantoin vegyület elõállítására
HUE050553T2 (hu) Eljárás A módosulatú kalkobutrol kristályos alakjának elõállítására
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
IL250211B (en) A process for the preparation of optically active isoxazoline compounds
DK3186227T3 (da) Nye sulfonylaminobenzamid-forbindelser som anthelmintika
IL252447B (en) Oral care composition
HUE056038T2 (hu) Cefalosporin-származék sója, annak kristályos szilárd alakja és eljárás annak elõállítására
DK3298042T3 (da) B-celledepletering som en diagnostisk markør
EP3177280A4 (en) Synthesis of 2,2,2-trifluoroethanethiol
ITUA20164040A1 (it) Procedimento per la preparazione di polimorfo a
TH1501006442A (th) รูปดัดแปรผลึกของอีโลไบซิแบต
UA29391S (uk) Тістечко листкове «кільце»